Quarterly ResultJul 29, 2026, 06:01 AM
Grifols H1 Net Profit Up 28.7% to €227M; Revenue €3.57B
AI Summary
Grifols reported strong first-half 2026 results, with revenue increasing 2.6% at constant currency to €3,574 million and net profit surging 28.7% to €227 million. The company also achieved a positive free cash flow pre-M&A of €91 million, an improvement of €103 million year-on-year. Strategic milestones include the successful refinancing of all 2027 debt maturities, redemption of a €500 million bond, and progress in its new Biopharma operating model and the Egypt plasma project. Grifols confirmed its full-year 2026 guidance.
Key Highlights
- H1 2026 revenue reached €3,574 million, up 2.6% at constant currency.
- Net profit increased by 28.7% to €227 million for the first half of 2026.
- Adjusted EBITDA was €854 million, up 2.4% cc, with a margin of 23.9%.
- Free cash flow pre-M&A improved to a positive €91 million, up €103 million year-on-year.
- Successfully refinanced all 2027 debt maturities and redeemed €500 million of a 2030 bond.
- Biopharma revenue grew 5.4% cc, led by a 12.8% cc increase in the immunoglobulin franchise.
- New organizational structure for Biopharma established, with dedicated U.S. and ROW units.
- Egypt project progressing, aiming for 3 million liters of plasma annually by 2029.
Price Impact
More from GRFS